The Oligonucleotide Safety Working Group (OSWG)

Nucleic Acid TherapeuticsVol. 22, No. 4 EditorialThe Oligonucleotide Safety Working Group (OSWG)Dave Schubert, Arthur A. Levin, Doug Kornbrust, Cindy L. Berman, Joy Cavagnaro, Scott Henry, Rosanne Seguin, Nicolay Ferrari, and Stephen B. ShrewsburyDave SchubertMediVector Inc., Boston, Massachusetts.Search for more papers by this author, Arthur A. LevinmiRagen Therapeutics, Rancho Santa Fe, California.Search for more papers by this author, Doug KornbrustPreclinsight, Reno, Nevada.Search for more papers by this author, Cindy L. BermanIndependent Consultant, Wayland, Massachusetts.Search for more papers by this author, Joy CavagnaroAccess BIO, Boyce, Virginia.Search for more papers by this author, Scott HenryIsis Pharmaceuticals Inc., Carlsbad, California.Search for more papers by this author, Rosanne SeguinTopigen Pharmaceuticals Inc. (part of the Pharmaxis Ltd. Group), Montreal, Canada.Search for more papers by this author, Nicolay FerrariTopigen Pharmaceuticals Inc. (part of the Pharmaxis Ltd. Group), Montreal, Canada.Search for more papers by this author, and Stephen B. ShrewsburyShrewd Consulting LLC, Cupertino, California.Search for more papers by this authorPublished Online:22 Aug 2012https://doi.org/10.1089/nat.2012.0383AboutSectionsView articleView Full TextPDF/EPUB ToolsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View article"The Oligonucleotide Safety Working Group (OSWG)." , 22(4), pp. 211–212FiguresReferencesRelatedDetailsCited ByConsiderations and recommendations for assessment of plasma protein binding and drug–drug interactions for siRNA therapeutics10 June 2022 | Nucleic Acids Research, Vol. 50, No. 11MicroRNAs and their delivery in diabetic fibrosisAdvanced Drug Delivery Reviews, Vol. 182Critical review of nucleic acid nanotechnology to identify gaps and inform a strategy for accelerated clinical translationAdvanced Drug Delivery Reviews, Vol. 181Preclinical Safety Assessment of Therapeutic Oligonucleotides1 January 2022Considerations of the Japanese Research Working Group for the ICH S6 & Related Issues Regarding Nonclinical Safety Assessments of Oligonucleotide Therapeutics: Comparison with Those of Biopharmaceuticals Yoko Hirabayashi, Kazushige Maki, Kiyoshi Kinoshita, Takahiro Nakazawa, Satoshi Obika, Misaki Naota, Kazuto Watanabe, Mutsumi Suzuki, Teruyo Arato, Aki Fujisaka, Osamu Fueki, Kosuke Ito, and Hiroshi Onodera25 March 2021 | Nucleic Acid Therapeutics, Vol. 31, No. 2Outcomes of the European Federation of Pharmaceutical Industries and Associations Oligonucleotide Working Group Survey on Nonclinical Practices and Regulatory Expectations for Therapeutic Oligonucleotide Safety Assessment Yann Tessier, William Achanzar, Lauren Mihalcik, Chidozie Amuzie, Patrik Andersson, Joel D. Parry, Jonathan Moggs, and Laurence O. Whiteley11 February 2021 | Nucleic Acid Therapeutics, Vol. 31, No. 1Opportunities, Barriers, and a Strategy for Overcoming Translational Challenges to Therapeutic Nucleic Acid Nanotechnology24 July 2020 | ACS Nano, Vol. 14, No. 8Emerging siRNA Design Principles and Consequences for Biotransformation and Disposition in Drug Development30 April 2020 | Journal of Medicinal Chemistry, Vol. 63, No. 12Preclinical safety assessments of mRNA-targeting oligonucleotide therapeuticsTranslational and Regulatory Sciences, Vol. 2, No. 3The Pharmacokinetics of 2′-O-Methyl Phosphorothioate Antisense Oligonucleotides: Experiences from Developing Exon Skipping Therapies for Duchenne Muscular Dystrophy Sieto Bosgra, Jessica Sipkens, Sjef de Kimpe, Cathaline den Besten, Nicole Datson, and Judith van Deutekom2 December 2019 | Nucleic Acid Therapeutics, Vol. 29, No. 6In-Vivo Degradation of DNA-Based Therapeutic BC 007 in Humans23 January 2019 | European Journal of Drug Metabolism and Pharmacokinetics, Vol. 44, No. 4Addressing barriers to effective cancer immunotherapy with nanotechnology: achievements, challenges, and roadmap to the next generation of nanoimmunotherapeuticsAdvanced Drug Delivery Reviews, Vol. 141RNA Fibers as Optimized Nanoscaffolds for siRNA Coordination and Reduced Immunological Recognition9 October 2018 | Advanced Functional Materials, Vol. 28, No. 48Genotoxicity Tests for Novel Oligonucleotide-Based Therapeutics22 June 2018Reproductive and Developmental Toxicity Testing Strategies for Oligonucleotide-Based Therapeutics22 June 2018Recommendations of the Oligonucleotide Safety Working Group's Formulated Oligonucleotide Subcommittee for the Safety Assessment of Formulated Oligonucleotide-Based Therapeutics Jennifer L. Marlowe, Violetta Akopian, Priya Karmali, Douglas Kornbrust, Jennifer Lockridge, and Sean Semple1 August 2017 | Nucleic Acid Therapeutics, Vol. 27, No. 4Locked nucleic acid (LNA)-based single-stranded oligonucleotides are not genotoxic10 March 2017 | Environmental and Molecular Mutagenesis, Vol. 58, No. 3OSWG Recommendations for Genotoxicity Testing of Novel Oligonucleotide-Based Therapeutics Cindy L. Berman, Scott A. Barros, Sheila M. Galloway, Peter Kasper, Frederick B. Oleson, Catherine C. Priestley, Kevin S. Sweder, Michael J. Schlosser, and Zhanna Sobol11 April 2016 | Nucleic Acid Therapeutics, Vol. 26, No. 2Immunological and hematological toxicities challenging clinical translation of nucleic acid-based therapeutics28 May 2015 | Expert Opinion on Biological Therapy, Vol. 15, No. 7Safety Pharmacology Evaluation of BiopharmaceuticalsConsiderations for the Preclinical Safety Evaluation of Biopharmaceuticals☆Considerations for Assessment of Reproductive and Developmental Toxicity of Oligonucleotide-Based Therapeutics Joy Cavagnaro, Cindy Berman, Doug Kornbrust, Tacey White, Sarah Campion, and Scott Henry11 September 2014 | Nucleic Acid Therapeutics, Vol. 24, No. 5Hepatotoxic Potential of Therapeutic Oligonucleotides Can Be Predicted from Their Sequence and Modification Pattern Peter H. Hagedorn, Victor Yakimov, Søren Ottosen, Susanne Kammler, Niels F. Nielsen, Anja M. Høg, Maj Hedtjärn, Michael Meldgaard, Marianne R. Møller, Henrik Ørum, Troels Koch, and Morten Lindow29 August 2013 | Nucleic Acid Therapeutics, Vol. 23, No. 5 Volume 22Issue 4Aug 2012 InformationCopyright 2012, Mary Ann Liebert, Inc.To cite this article:Dave Schubert, Arthur A. Levin, Doug Kornbrust, Cindy L. Berman, Joy Cavagnaro, Scott Henry, Rosanne Seguin, Nicolay Ferrari, and Stephen B. Shrewsbury.The Oligonucleotide Safety Working Group (OSWG).Nucleic Acid Therapeutics.Aug 2012.211-212.http://doi.org/10.1089/nat.2012.0383Published in Volume: 22 Issue 4: August 22, 2012PDF download